Marco Falasca, PhD

Metabolic Signalling Group, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation; Research Institute, Curtin University, Perth, Western Australia 6102, Australia

Marco Falasca was educated in Italy at the University of Camerino, University of Bari and at the Consorzio Mario Negri Sud. He then was involved in Postdoctoral training at the Department of Pharmacology, New York University Medical Center, Department of Pharmacology with Prof Joseph Schlessinger from 1995 to 1998. In 1998, Prof Falasca took up a position as Head of the Unit of Physiopathology of Cell Signalling within the Consorzio Mario Negri Sud.

In 2001 Prof. Falasca moved to London, UK, where he was appointed as Principal Research Fellow, Senior Lecturer within the Department of Medicine at the University College London. In 2007 he was appointed as Professor of Molecular Pharmacology at Queen Mary University of London within the Blizard Institute.

In 2014 he was appointed as Professor in Metabolism at the School of Biomedical Sciences, Curtin University, Perth, Australia. Research in Prof Falasca’s lab is mostly focused on intracellular signals regulated by specific lipids that act as “second messengers”. Current specific projects are dedicated to the investigation of the mechanisms involved in the development and progression of pancreatic cancer. He is particularly interested in metabolic pathways in cancer development and progression.